FDA panel considers a first-of-its-kind flu vaccine using mRNA technology

▤ Summary

FDA advisers backed Moderna’s mRNA flu vaccine, bringing it a step closer to U.S. approval. The shot targets older adults first, with Moderna seeking approval for ages 50 to 64 and authorization for people 65 and older. The company says the vaccine could be manufactured quickly and better match future flu strains. The FDA is expected to make a final decision by early August, and Moderna is already planning follow-up studies in larger older-adult populations.

▦ Linked Companies